Brentuximab vedotin - a highly potent Therapy in cutaneous T-Cell-Lymphoma

被引：0
|
作者：
Pax, A. T.
Stadler, R.
机构：
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2014年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：2 / 2
页数：1
相关论文
共 50 条
  • [31] Clinical Experience With Brentuximab Vedotin in Treating Cutaneous T-Cell Lymphoma: A Retrospective Review From China
    Pang, Zhiyu
    Zhang, Shan
    Liu, Zhaorui
    Zhang, Wei
    Liu, Jie
    DERMATOLOGIC THERAPY, 2024, 2024
  • [32] Real-world evidence study of brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma
    Mitteldorf, C.
    de Masson, A.
    Beylot-Barry, M.
    Wobster, M.
    Zomas, A.
    Stache, V.
    Assaf, C.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S77 - S78
  • [33] Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine
    Sophie Voruz
    Laurence de Leval
    Anne Cairoli
    Experimental Hematology & Oncology, 10
  • [34] Brentuximab vedotin in anaplastic large cell lymphoma
    Skarbnik, Alan P. Z.
    Smith, Mitchell R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 633 - 639
  • [35] Primary cutaneous peripheral T-cell lymphoma not otherwise specified (NOS) and successful use of brentuximab vedotin
    Makris, Nikolaos
    Finck, Stefanie
    Kirchner, Kathrin
    von den Driesch, Peter
    AKTUELLE DERMATOLOGIE, 2023, 49 (06) : 265 - 267
  • [36] A Successful Experience with Brentuximab Vedotin in Relapsing/Refractory Cutaneous T-Cell Lymphoma: Two Case Reports
    Gorenkova, Liliya
    Kravchenko, Sergey K.
    Kovrigina, Alla M.
    Savchenko, Valery G.
    BLOOD, 2018, 132
  • [37] Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin
    Sasapu, Appalanaidu
    Dunn, Andrew L. J.
    Gardner, Jerad
    Wong, Henry K.
    BMJ CASE REPORTS, 2021, 14 (07)
  • [38] A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma
    Barta, Stefan K.
    Feldman, Tatyana A.
    DeSimone, Jennifer A.
    Kim, Ellen
    Devajaran, Karthik
    Yang, Yibin
    Fung, Henry C.
    Mahvish, Tafseer
    Nakhoda, Shazia
    Khan, Nadia
    BLOOD, 2022, 140 : 6543 - 6544
  • [39] A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma
    Barta, Stefan K.
    Feldman, Tatyana A.
    DeSimone, Jennifer A.
    Kim, Ellen
    Devajaran, Karthik
    Wiest, David
    Fung, Henry C. H.
    Fisher, Richard I.
    Tan, Carlyn
    Khan, Nadia
    BLOOD, 2020, 136
  • [40] Cutaneous, non-epitheliotropic T-cell-lymphoma in a domestic cat
    Runge-Harms, U
    Loesenbeck, G
    KLEINTIERPRAXIS, 2000, 45 (08): : 629 - +
12345